found that EGR1 expression levels were significantly higher in ovarian cancer tissues with low ERCC1 expression than in ovarian cancer tissues with high ERCC1 expression, suggesting that EGR1 expression is positively correlated with potential cisplatin-sensitive ovarian cancer, since ERCC1 is widely accepted as a biomarker of platinum resistance (28). The gene discussed is ERCC1; the disease is ovarian cancer.